Objective: The Mayo Test Drive (MTD) screening battery is a digital, self-administered, web-based cognitive assessment (Stricker et al., 2025 TCN). We aimed to compare diagnostic accuracy of raw versus normative score approaches to distinguishing cognitively unimpaired (CU) from mild cognitive impairment/mild dementi...
Morgan A. Hughes, Alyssa N. Kaser, Elizabeth A. Boots et al.· Archives of Clinical Neurops...· 0 citations
Abstract INTRODUCTION Biological Alzheimer's disease (AD) pathology does not fully explain the marked heterogeneity in clinical severity or progression. We investigated whether patient‐derived induced microglia‐like cell (iMG) profiles capture a functional dimension of AD progression beyond conventional plasma biomarke...
Min-Young Noh, Yeonsil Moon, Sung-Woo Kang et al.· Alzheimer's & Dementia· 0 citations
Cognitive changes in the asymptomatic stages of Alzheimer disease (AD) are subtle and difficult to detect using conventional cognitive tests. High‐frequency smartphone‐based testing may improve sensitivity to these changes, but generational differences in technology use could influence performance. We examined generati...
Samhita Katteri, Hannah M. Wilks, Matthew S. Welhaf et al.· Alzheimer's & Dementia· 0 citations
BACKGROUND AND OBJECTIVES
Plasma phosphorylated tau (p-tau) 217 is increasingly used for Alzheimer disease (AD) diagnosis and treatment decisions but may be discordant with established AD biomarkers. False-positive (FP) plasma results may lead to overtreatment and false-negative (FN) results to missed or delayed diseas...
D. Shir, A. Algeciras-Schimnich, Y. Piura et al.· Neurology· 0 citations
Introduction: Frontotemporal lobar degeneration (FTLD) is a devastating disease that commonly results in early onset dementia, yet its rarity and heterogeneity limit large-scale research and clinical trials. Remote monitoring via low-burden digital health tools may overcome these barriers. We evaluated clinical utility...
E. Paolillo, Sreya Dhanam, J. Taylor et al.· medRxiv· 0 citations
BACKGROUND AND OBJECTIVES
Mild cognitive impairment (MCI), Alzheimer disease (AD), and AD-related dementias (ADRD) are growing public health concerns. Regional, demographic, and clinical differences in these diagnoses and associated comorbid conditions may inform strategies to improve prevention, care, and outcomes. To...
Sahar F. Zafar, L. Moura, Brittany Gorham et al.· Neurology Clinical Practice· 0 citations
INTRODUCTIONCognitive characterization is increasingly important for Alzheimers disease treatment decisions, highlighting the need for scalable cognitive assessment. We evaluated the diagnostic accuracy of a remote self-administered cognitive screening battery, Mayo Test Drive (MTD), across clinically and biologically...
N. Stricker, Elizabeth A. Boots, Rita L. Taylor et al.· medRxiv· 0 citations
FDG-PET demonstrated a numerical association between carotid stenosis severity and reduced cerebral glucose metabolism, but this did not reach statistical significance.
Mahmoud Afia, S. Vallamchetla, R. Tatit et al.· Neuroimage: Reports· 0 citations
Findings support the potential value of EOAD-signature atrophy as an MRI-based biomarker for individualized prognostication and clinical trial stratification and support the potential value of EOAD-signature atrophy as an MRI-based biomarker for individualized prognostication and clinical trial stratification.
T. Paranhos, Yuta Katsumi, M. Brickhouse et al.· Neurology· 0 citations
Plasma p‐tau217 and p‐tau217/Aβ42 reliably identify non‐Hispanic White individuals with symptomatic and pre‐clinical AD. However, performance across ethnoracially diverse groups remains unknown.
Y. Piura, P. Aduen, Leah Schecter et al.· Alzheimer's & Dementia· 0 citations
Proteomic differences in synapse integrity, tau post-translational modification, and ubiquitination associated with age at symptomatic onset and corticolimbic distribution of tangle pathology are observed.
S. R. Dunlop, Sarah J. Lincoln, Zhongwei Peng et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
